Clinical Trial Detail

NCT ID NCT03804515
Title A Mass Balance and Pharmacokinetics Study of 14C-Labeled Poziotinib in Cancer Patients Suitable for Treatment With Poziotinib
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Spectrum Pharmaceuticals, Inc
Indications

Advanced Solid Tumor

Therapies

Poziotinib

Age Groups: senior adult

Additional content available in CKB BOOST